Prevalence of non‐alcoholic fatty liver and liver fibrosis in patients with moderate–severe psoriasis: A cross‐sectional cohort study

Magdaleno‐Tapial, Jorge; Valenzuela‐Oñate, Cristian; Salvador, José María Ortiz; Martínez‐Doménech, Álvaro; García-Legaz-Martínez, Marta; Alonso‐Carpio, Miriam; Tamarit-García, J.J.; Diago-Madrid, Moisés; Sánchez‐Carazo, J.L.; Pérez‐Ferriols, A.

doi:10.1111/ajd.13175

Cited by 18 publications

(22 citation statements)

References 16 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In keeping with previous reports 7,25,27,30 , our patients with NAFLD had a greater PASI compared to those without. However, severity scores in our patients were generally low because most were under systemic therapy, so caution is warranted when interpreting this result.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

Belinchón-Romero

Bellot

Romero‐Pérez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Psoriasis and non-alcoholic fatty liver disease (NAFLD) are both inflammatory diseases. The study objective was to estimate the risk of NAFLD, non-alcoholic steatohepatitis, and liver fibrosis (by liver stiffness and liver biopsy) in patients with psoriasis and to determine the epidemiological, clinical, immunological (TNF-α, IL-2, IL-6, IL-12, IL-17, IL-23, and TGF-β) characteristics, and bacterial translocation. Of the 215 psoriatic patients included, 91 presented NAFLD (prevalence: 42.3%). Compared to patients with psoriasis alone, those with NAFLD were significantly more likely to have metabolic syndrome, diabetes, dyslipidemia, body mass index ≥ 30 kg/m2, homeostatic model assessment of insulin resistance ≥ 2.15, and greater psoriasis area severity index. NAFLD patients also had significantly higher levels of TNF-α (p = 0.002) and TGF-β (p = 0.007) and a higher prevalence of bacterial translocation (29.7% vs. 13.7%; p = 0.004). Liver stiffness measurement was over 7.8 kPa in 17.2% (15/87) of NAFLD patients; 13 of these underwent liver biopsy, and 5.7% (5/87) had liver fibrosis, while 1.1% (1/87) had advanced fibrosis or non-alcoholic steatohepatitis. In conclusion the prevalence of NAFLD in patients with psoriasis is high and associated with a higher prevalence of metabolic syndrome features, bacterial translocation and a higher pro-inflammatory state. It is worth mentioning that liver fibrosis and non-alcoholic steatohepatitis are not frequent in this population of patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…However, severity scores in our patients were generally low because most were under systemic therapy, so caution is warranted when interpreting this result. When analyzing specific psoriasis treatments, only acitretin appeared to be associated with NAFLD; however, other studies have not detected any relationship 25,31,32 .…”

Section: Discussionmentioning

confidence: 84%

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

Belinchón-Romero

Bellot

Romero‐Pérez

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Psoriasis is an immune-mediated, chronic inflammatory skin disease of complex patomechanism. Several studies have shown that psoriasis is associated with systemic disorders specially metabolic syndrome (MS), which is defined as a constellation of insulin resistance, obesity, hyperlipidemia and hypertension [1,2] Psoriatic patients are also predisposed to other comorbidities like: inflammatory bowel diseases, cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD) [3][4][5]. It has been established that the release of inflammatory molecules and cytokines play an important role in metabolic disturbances and atherosclerosis in the course of psoriasis [6].…”

Section: Introductionmentioning

confidence: 99%

Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

et al. 2021

View full text Add to dashboard Cite

Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband—ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas–liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P < 0.001). FABP5 in patients with PASI > 20 was higher compared to the mild group (PASI < 10) (P < 0.001) and serum FABP5 correlated positively with PASI score (r = 0.41, P < 0.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P < 0.001) was observed and accompanied by decrease of the serum FABP5 (P = 0.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.

show abstract

“…Several studies have shown that psoriasis is associated with systemic disorders specially metabolic syndrome (MS), which is de ned as a constellation of insulin resistance, obesity, hyperlipidemia and hypertension [1,2] Psoriatic patients are also predisposed to other comorbidities like: in ammatory bowel diseases, cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD) [3][4][5]. It has been established that the release of in ammatory molecules and cytokines play an important role in metabolic disturbances and atherosclerosis in the course of psoriasis [6].…”

Section: Introductionmentioning

confidence: 99%

Serum Fatty Acid Binding protein 5 (FABP5) as a Potential Biomarker of Inflammation in Psoriasis.

Kozłowska

Myśliwiec

Harasim-Symbor

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Psoriasis is an immune-mediated chronic inflammatory disease with cardiometabolic comorbidities. Fatty acid binding protein 5 (FABP5) is elevated in human psoriatic keratinocytes and could be potentially involved in systemic metabolic disturbances. The aim of the study was to evaluate serum FABP5 in psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband - ultraviolet B (NB-UVB). Methods: Seventy four patients with active plaque-type psoriasis and 30 healthy controls were enrolled in the study. Thirty patients were treated with NB-UVB. Patients were divided into subgroups based on their disease severity measured by Psoriasis Area and Severity Index (PASI) and Body Mass Index (BMI). The serum concentrations of FABP5 were measured using commercially available Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Total serum fatty acids content and composition was measured by gas–liquid chromatography. Results: Serum FABP5 levels in psoriatic patients (both obese and non-obese) were higher versus control group (P <0.001). FABP5 in patients with PASI >20 was higher compared to the mild group (PASI <10) (P <0.001) and serum FABP5 correlated positively with PASI score (r=0.41, P <0.001). There was also positive correlation between FABP5 and basic inflammation indices: C-reactive protein, white blood cell count and the platelet count. Decrease of PASI after NB-UVB treatment (P <0.001) was observed and accompanied by decrease of the serum FABP5 (P=0.007). Conclusion: FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances and might be the missing link between psoriasis and metabolic disturbances.

show abstract

Prevalence of non‐alcoholic fatty liver and liver fibrosis in patients with moderate–severe psoriasis: A cross‐sectional cohort study

Cited by 18 publications

References 16 publications

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

Serum Fatty Acid Binding protein 5 (FABP5) as a Potential Biomarker of Inflammation in Psoriasis.

Contact Info

Product

Resources

About